Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,602 recruiting studies in this area right now.
By phase
- Not applicable9,790
- Phase 24,449
- Phase 12,736
- Phase 1/Phase 21,687
- Phase 31,397
- Phase 2/Phase 3280
- Phase 4263
Top conditions
- Breast Cancer1,227
- Cancer661
- Prostate Cancer654
- Colorectal Cancer491
- Lung Cancer424
- Ovarian Cancer338
- Multiple Myeloma332
- Gastric Cancer296
- Acute Myeloid Leukemia292
- Pancreatic Cancer290
- Hepatocellular Carcinoma283
- Solid Tumor257
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer227
- Endometrial Cancer206
- Advanced Solid Tumors193
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University313
- Sun Yat-sen University290
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)285
- Mayo Clinic240
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center147
- AstraZeneca134
- University Health Network, Toronto125
Where studies are running
- California1,424
- Texas638
- Arizona513
- Florida448
- Alabama420
- New York409
- Massachusetts343
- Maryland329
- New Jersey269
- Pennsylvania241
Recruiting studies20,602 total
- NCT06597721RecruitingPhase 1
ADCE-T02 for advanced solid tumors
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
Rogers, ArkansasAges 18 years+ - NCT07115485RecruitingPhase 2
Study of HLX43 for advanced stomach or junction cancer
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
BeijingAges 3 weeks–2 months - NCT07240857Enrolling by invitationEarly Phase 1
CAR-T cell injection for advanced prostate cancer
This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.
Hangzhou, ZhejiangAges 18 years+ - NCT07541924Recruiting
Image-Guided Colonoscopy: Patient Experience and Doctor Efficiency
This study tests whether using CT scan images to guide doctors during colonoscopy (a camera exam of your colon) improves how well the procedure goes and reduces doctor stress. You'll answer questions about your experience before and after the procedure.
Beijing, Beijing MunicipalityAges 18–80 - NCT05685173RecruitingPhase 1
Study safety of REGN5837 with odronextamab in adult B-cell lymphoma
This Phase 1 trial tests whether a new medicine (REGN5837) given with odronextamab is safe in adults with aggressive B-cell non-Hodgkin lymphoma. It may help researchers learn if this combination can work for patients whose disease has progressed after earlier treatments.
Duarte, CaliforniaAges 18 years+ - NCT07541664Recruiting
Digital Mind-Body Therapy for Breast Cancer Patients
This study tests a smartphone app that combines relaxation techniques and mental health support for women receiving chemotherapy before breast cancer surgery. It aims to reduce anxiety, depression, sleep problems, and emotional distress during cancer treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05754684RecruitingPhase 2
Immunotherapy with donor NK cells for relapsed neuroblastoma
This trial studies a “quadruple immunotherapy” treatment using donor immune cells (NK cells) to fight neuroblastoma that has come back or did not respond to prior therapy. It may help by boosting the body’s immune attack, but only certain children meet the safety and donor requirements.
Hong KongAges Up to 18 years - NCT06559553RecruitingPhase 1/Phase 2
Selinexor, pegaspargase, and dexamethasone for NK/T-cell lymphoma
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
Zhengzhou, HenanAges 18–70 - NCT07115667RecruitingPhase 2
Radiation and antibody therapy for bone plasmacytoma
This trial tests a new combination of radiation therapy and a bispecific antibody (a drug that helps your immune system attack cancer cells) for people with a single bone plasmacytoma that has only a small number of abnormal cells in the bone marrow. It aims to see if this approach can control the disease better than radiation alone.
TianjinAges 18–78 - NCT07108725Recruiting
Better MRI scan for bile duct blockage
This trial is testing if a special MRI technique called diffusion-weighted imaging (DWI) can better find bile duct blockages caused by tumors, compared with standard MRI. If you have symptoms like yellow skin or dark urine and need a detailed look at your bile ducts, this might help your doctor make a more accurate diagnosis.
CairoAges 18 years+ - NCT07110584RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called MDX2004 for people with advanced solid tumors (cancer that has spread or can't be removed). The goal is to see if the drug is safe and if it helps shrink tumors.
Liverpool, New South WalesAges 18 years+ - NCT07276932Recruiting
Acupoint paste for constipation after chemo
This study tests whether applying a special paste to acupoints (specific points on your body) can help relieve constipation and boost energy (qi) in people with colorectal cancer who've had chemotherapy. It's for patients who feel weak and have trouble with constipation after treatment.
Hangzhou, ZhejiangAges 18 years+ - NCT07110883RecruitingPhase 1
Study of SYS6023 for advanced solid tumors
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
Harbin, HeilongjiangAges 18 years+ - NCT05798845RecruitingPhase 2
Toripalimab plus radiation before surgery for stage II–IIIA lung cancer
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07107165Recruiting
Support for stem cell transplant patients and caregivers
This study tests a program to help stem cell transplant patients and their family caregivers cope with the stress of treatment. If you are getting a stem cell transplant at the University of Pittsburgh and have a caregiver who can join, you may be able to take part.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06867588Recruiting
Adding PSMA PET to MRI for prostate cancer detection
This study is testing whether a special scan called a PSMA PET can help find significant prostate cancer in men who are already scheduled for an MRI-guided biopsy. It aims to see if combining the two scans gives a better picture of which prostate areas need to be biopsied.
BrusselsAges 18 years+ - NCT06594991RecruitingPhase 2
A study of three immunotherapy drugs for advanced melanoma
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06835725RecruitingPhase 2
Comparing two prostate radiation schedules for intermediate risk
This trial compares giving radiation in 2 treatments versus 5 treatments for prostate cancer that hasn't spread. It's for men with low or intermediate risk prostate cancer who are healthy enough to undergo a short course of targeted radiation.
Surrey, British ColumbiaAges 18 years+ - NCT06265688RecruitingPhase 1
First study of CX-2051 for advanced solid tumors
This study is testing a new drug called CX-2051 for people with advanced solid tumors that have not responded to standard treatments. The drug is a type of targeted therapy that delivers chemotherapy directly to cancer cells, and the goal is to see if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07105033Recruiting
Focused ACT for advanced cancer patients
This study tests a counseling program called Focused ACT (FACT) to help patients with advanced cancer cope with stress and death anxiety. It involves talking with a counselor about important areas of your life.
Houston, TexasAges 18 years+ - NCT07101601RecruitingPhase 1
Testing DM5167 for advanced solid tumors with BRCA mutations
This trial is testing a new drug called DM5167 for people whose advanced solid tumors have a BRCA1 or BRCA2 gene mutation. The goal is to see if the drug can shrink tumors or slow their growth.
Gyeonggi-doAges 19 years+ - NCT07235930RecruitingPhase 3
New drug combo for advanced pancreatic cancer
This trial tests a combination of chemotherapy plus two targeted drugs (serplulimab and bevacizumab) against chemotherapy alone for pancreatic cancer that cannot be removed by surgery or has spread. This approach may help shrink or stabilize the tumor longer.
Hangzhou, ZhejiangAges 18–75 - NCT07100704RecruitingPhase 2
Nivolumab for recurrent olfactory neuroblastoma
This trial tests the drug nivolumab for people with a rare nasal tumor (olfactory neuroblastoma) that has come back or spread and cannot be treated with surgery or radiation. You must have already tried chemotherapy and it stopped working. The goal is to see if nivolumab can shrink the tumor or slow its growth.
Kashiwa, ChibaAges 18 years+ - NCT07233252RecruitingPhase 2
Tislelizumab and chemotherapy for kidney pelvis cancer
This trial tests a combination of an immunotherapy drug (tislelizumab) and a chemotherapy drug (nab-paclitaxel) to treat kidney pelvis cancer while trying to save as much kidney function as possible. It may be an option if you have a small tumor in the kidney pelvis and are scheduled for a laser procedure.
Tianjin, Outside U.S.Ages 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,602 recruiting oncology studies from the U.S. registry right now, out of 31,289 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.